Trial 4B-16-1


A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  David Quinn, M.D.
Other Trial Staff:  Cheryl Kefauver, Coordinator, Victoria Banerjee, Coordinator, Lagrimas Ilagan, D.M., Roberto Tejada, D.M., Taison Tran, Coordinator, Bartolo Santos, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.